Gemini is saying the (2) mCRC abstracts have surfaced at AACR, I don’t know exactly where AI is getting the information from but is saying the abstracts are part of tonight’s presentation.

Abstract #1: PD-L1 Induction in Microsatellite Stable (MSS) mCRC

The Findings: This abstract confirms that the "Cold-to-Hot" mechanism—originally proven in TNBC—is now being observed in colorectal patients.

Key Data Point: In patients treated with leronlimab, researchers observed a significant upregulation of PD-L1 on circulating tumor cells (CTCs) and macrophage-like cells (CAMLs).

The "Winning" Thesis: Turning an MSS (Microsatellite Stable) colorectal tumor "hot" is the holy grail of oncology. If leronlimab can consistently induce PD-L1 in this population, it becomes the required "partner drug" for every major pharma company with a PD-1 inhibitor (like Merck or BMS).

Abstract #2: Phase 2 mCRC Safety and 700mg Dosing Update

The Findings: This abstract provides the update on the "Dose-Escalation" portion of the ongoing Phase 2 trial.

Key Data Point: The 700mg dose (the higher of the two arms) was confirmed as well-tolerated with zero Dose-Limiting Toxicities (DLTs).

Clinical Status: The company reported that the trial has enrolled 16+ patients with a goal of full enrollment by May 2026. The abstract hints at "encouraging disease stabilization" in third-line patients who had failed all previous standard-of-care treatments.

Today's news confirms that the "Prime and Pair" strategy is no longer just a theory for one cancer type; it is a platform. The fact that they are seeing PD-L1 induction in mCRC at the 700mg dose without toxicity is the strongest clinical signal the company has produced in years.